A fairly new drug called olaparib was approved by the FDA in 2014 to treat ovarian cancer in women with BRCA mutations. However, recent studies have shown that different types of cancer can be treated with this drug, and that the target demographic extends beyond those with the specific genetic mutation. In a phase II clinical of men with prostate cancer, 13 of 15 men with DNA repair mutations responded to olaparib. Leaders of the study at the Institute of Cancer Research and the Royal Marsden NHS Trust in London have presented their findings at a meeting of the American Association for Cancer research and hope to move forward with clinical trials.

The Pharmaceutical Journal
See presentation abstract here